Amendment No. 35 **U.S. NUCLEAR REGULATORY COMMISSION** MATERIALS LICENSE Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below. Licensee In accordance with letter dated August 11, 2015, 1. Midwest Division - LSH, LLC 3. License number 24-24660-01 is amended in its entirety to read as follows: (d/b/a Lee's Summit Hospital) 2. 2100 S.E. Blue Parkway 4. Expiration date March 31, 2022 5. Docket No. 030-29074 Lee's Summit, MO 64063 Reference No. 6. Byproduct, source, and/or special 7. Chemical and/or physical form 8. Maximum amount that licensee may possess at any one time under this license nuclear material A. As needed A. Any byproduct material A. Anv permitted by 10 CFR 35.100 B. As needed B. Any byproduct material B. Any permitted by 10 CFR 35.200 C. 1 curie C. Any byproduct material C. Any permitted by 10 CFR 35.300 D. 2 millicuries D. Any byproduct material D. Prepackaged Kits permitted by 10 CFR 31.11 9. Authorized use: A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100. B. Any imaging and localization study permitted by 10 CFR 35.200. C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300. D. In vitro studies. CONDITIONS Licensed material may be used or stored only at the licensee's facilities located at 2100 S.E. Blue 10. Parkway, Lee's Summit, Missouri The Radiation Safety Officer (RSO) for this license is Aaron M. Lewis, M.D. 11. 12. Licensed material is only authorized for use by, or under the supervision of: A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14. B. The following individuals are authorized users for medical use as indicated:

PAGES

4

OF

1

PAGE

NRC FORM 374

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

SUPPLEMENTARY SHEET

PAGE 2 of 4 PAGES

License Number 24-24660-01

Docket or Reference Number 030-29074

Amendment No. 35

Material and Use Authorized Users 10 CFR 35.100, 35.200, 35.300, and 31.11. William M. Chase, M.D. 10 CFR 35.100, 35.200, 35.300, and 31.11. Craig M. Bruner, M.D. Douglas W. Nemmers, M.D. 10 CFR 35.100, 35.200, 35.300, and 31.11. 10 CFR 35.100, 35.200, 35.300, and 31.11. Michael B. Parsa, M.D. 10 CFR 35.100, 35.200, and 35.300. Jeffrey R. Conaway, M.D. 10 CFR 35.100, 35.200, and 35.300. John F. Eurich, M.D. 10 CFR 35.100, 35.200, 35.300, and 31.11. Kelly Hart, M.D. 10 CFR 35.100, 35.200, 35.300, and 31.11. Rick Moritz, M.D. 10 CFR 35.100, 35.200, 35.300, and 31.11. Sarah L. Sherard, M.D. 10 CFR 35.100, 35.200, 35.300, and 31.11. Donald J. Stallard, M.D. 10 CFR 35.200. Daniel H. Dunker, M.D. 10 CFR 35.200. James E. Sear, M.D. 10 CFR 35.100, 35.200, 35.300 (limited to the use of Michael Brian Robertson, M.D. sodium iodide I-131), and 31.11. 10 CFR 35.100, 35.200, 35.300, and 31.11. Bradley McIlnay, M.D. 10 CFR 35.100, 35.200, and 35.300. Vandana Halder, M.D. 10 CFR 35.100, 35.200, and 35.300. Leo J. Splitter, M.D. 10 CFR 35.100, and 35.200. Craig B. McClure, M.D. 10 CFR 35.100, 35.200, and 35.300. Robert A. Wood, Jr., M.D. 10 CFR 35.100, 35.200, and 35.300 (limited to the oral Jason Eric Himmel, M.D. administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries). 10 CFR 35.100, 35.200, and 35.300 (limited to the use of Michael J. Brigg, M.D. sodium iodide I-131). 10 CFR 35.100, 35.200, and 35.300 (limited to the use of Nathaniel R. Jewell, M.D. sodium iodide I-131). 10 CFR 35.100, 35.200, and 35.300 (limited to the oral Richard Cronemeyer, M.D. administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).

| NRC | FORM 374A | U.S. NUCLEAR REGUL | ATORY COMMISSION | PAGE | 3 of | 4 | PAGES | | | |
|---------------------|---------------------------------|---|------------------|---|------|-----|----------|--|--|--|
| | | MATERIALS LICENSI SUPPLEMENTARY SHEE | | License Number 24-24660-01 Docket or Reference Number 030-29074 Amendment No. 35 | | | <u>.</u> | | | |
| | Author | <u>ized Users</u> | Material a | nd Use | | | | | | |
| | Christo | Christopher McKinney, M.D. | | 10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries). | | | | | | |
| | Aaron | M. Lewis, M.D. | 10 CFR 3 | 5.100, 35.200, and 35.300. | | | | | | |
| | Brian A | A. Fletcher, M.D. | | 10 CFR 35.100, 35.200, and 35.300 (limited to the use of sodium iodide I-131). | | | | | | |
| | Nathar | Nathan S. Johnson, M.D.10 CFR 35.100, 35.200, and 35.300 (limited to the use o sodium iodide I-131). | | | | | | | | |
| | Amy P | Amy P. Oberhelman, M.D. | | 10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131). | | | | | | |
| | Sujit R. Gandhari, M.D., M.P.H. | | | 10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131). | | | | | | |
| | Daniel | T. Finn, M.D. | | 5.100, 35.200, and 35.300 (li tion of sodium iodide I-131). | | the | oral | | | |
| | Curtis T. Selser, M.D. | | | 10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131). | | | | | | |
| Mary Mitchell, M.D. | | | | 10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131). | | | | | | |
| | | | | | | | | | | |
| 13. | The licensee 10 CFR Part | in accordance with the provis active Material." | sions of | \$` | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |

| NRC FORM 374A | U.S. NUCLEAR REGULATORY COMMISSION | 1 | PAGE | 4 | of | 4 | PAGES |
|---|--|---|------|---|----|---|-------|
| <u>, , , , , , , , , , , , , , , , , , , </u> | | License Number 24-24660-01 | | | | | |
| | MATERIALS LICENSE SUPPLEMENTARY SHEET | Docket or Reference Number 030-29074 | r | | | | |
| | | Amendment No. 35 | | | | | |
| | | | | | | | |

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated September 29, 2011 (with attachments) (ML112730520).

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

By Cassandra F. Frazier

Cassandfa F. Frazier Materials Licensing Branch / Region III

Date NOV 1 8 2015